>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:

  • X +6.4% (issues upside EPS guidance), CNC +2.3% (raises FY22 outlook ahead of Investor Day; authorizes $3.0 bln increase to existing stock repurchase program)

Other news:

  • REV +81% (Reliance mulling buyout of REV according to Economic Times)
  • EFC +5% (reports book value per share)
  • JG +4.9% (receives RMB15 mln in special support funding from the Shenzhen Development and Reform Commission)
  • CTRN +4.4% (names new CFO)
  • ROKU +4.2% (ROKU and
  • WMT announce partnership to bring comerce to TV ads)
  • SRRA +3.8% (announces submission of new drug application for Momelotinib to FDA)
  • BITF +3.8% (entered into an equipment financing agreement with initial funding of $37 million)
  • BHC +3% (provides update on Solta Medical; IPO process suspended in light of market conditions)
  • ZIP +2.9% (authorizes $150 mln increase to share repurchase program)
  • REAX +2.5% (surpasses milestone of 5000 agents)
  • BGS +2.4% (forms four business units)
  • WPC +2.3% (increases dividend)
  • UWMC +2.2% (CFO takes leave of absence for health reasons)
  • ZI +1.8% (settles lawsuit with Bombora)
  • TWI +1.6% (entered into a global long-term agreement with Deere (DE) on June 13 to supply wheels and tires)
  • DAN +1.5% (awarded a $2.7 million (£2 million) grant to develop an e-Powertrain for OX Delivers)
  • AJRD +1.4% (CEO Eileen Drake and Committee for Aerojet Rocketdyne Shareholders and Value Maximization Extremely Pleased with Delaware Court's Opinion)
  • GVA +1.3% (awarded two contracts worth a combined $38 mln)
  • OAS +1.2% (declares $15 special dividend in connection with closing of merger with WLL)
  • OEC +1% (to raise prices for rubber carbon black products)
  • JATT +1% (JATT Acquisition Corp and Zura Bio Limited announce definitive business combination agreement to create NYSE listed biotechnology company)

Analyst comments:

  • AZEK +4.7% (upgraded to Buy from Neutral at BofA Securities)
  • COF +2.1% (upgraded to Outperform from Neutral at Robert Baird)
  • AXP +2% (upgraded to Outperform from Neutral at Robert Baird)